Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
1,961
Views
1
CrossRef citations to date
0
Altmetric
Research Article

miR-140-3p attenuated the tumorigenesis of multiple myeloma via attenuating BZW2

Xingxing LongDepartment of Hematology, The 1st Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, People’s Republic of ChinaView further author information
,
Junjun LiDepartment of Hematology, The 1st Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, People’s Republic of ChinaView further author information
,
Feng WenDepartment of Hematology, The 1st Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, People’s Republic of ChinaView further author information
,
Yixiong CaoDepartment of Hematology, The 1st Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, People’s Republic of ChinaView further author information
,
Zeyu LuoDepartment of Hematology, The 1st Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, People’s Republic of ChinaView further author information
&
Cong LuoDepartment of Hematology, The 1st Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 173-180 | Published online: 24 Jan 2022

References

  • Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060.
  • Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
  • Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(Suppl. 1):62–65.
  • Gowda PS, Wildman BJ, Trotter TN, et al. Runx2 suppression by miR-342 and miR-363 inhibits multiple myeloma progression. Mol Cancer Res. 2018;16(7):1138–1148.
  • Hu Y, Liu H, Fang C, et al. Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma. Cancer Res. 2020;80(10):2031–2044.
  • Wu H, Liu C, Yang Q, et al. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4. Autophagy. 2020;16(4):683–697.
  • Jiang W, Li T, Wang J, et al. miR-140-3p suppresses cell growth and induces apoptosis in colorectal cancer by targeting PD-L1. Onco Targets Ther. 2019;12:10275–10285.
  • Wang Y, Chen J, Wang X, et al. miR-140-3p inhibits bladder cancer cell proliferation and invasion by targeting FOXQ1. Aging (Albany NY). 2020;12(20):20366–20379.
  • Zhou Y, Wang B, Wang Y, et al. miR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28. Oncol Lett. 2019;17(4):3835–3841.
  • Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009;114(25):e20–e26.
  • Jin X, Liao M, Zhang L, et al. Role of the novel gene BZW2 in the development of hepatocellular carcinoma. J Cell Physiol. 2019;234(9):16592–16600.
  • Wang S, Bai W, Huang J, et al. Prognostic significance of BZW2 expression in lung adenocarcinoma patients. Int J Clin Exp Pathol. 2019;12(12):4289–4296.
  • Huang L, Chen S, Fan H, et al. BZW2 promotes the malignant progression of colorectal cancer via activating the ERK/MAPK pathway. J Cell Physiol. 2020;235(5):4834–4842.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
  • Ma J, Zhang F, Sun P. miR-140-3p impedes the proliferation of human cervical cancer cells by targeting RRM2 to induce cell-cycle arrest and early apoptosis. Bioorg Med Chem. 2020;28(3):115283.
  • Hu C, Zou Y, Jing LL. miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1. J Biosci. 2020;45(48):1–11.
  • Wang J, Zhu M, Zhou X, et al. MiR-140-3p inhibits natural killer cytotoxicity to human ovarian cancer via targeting MAPK1. J Biosci. 2020;45(66):1–10.
  • Zhao K, Li X, Chen X, et al. Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression. Eur J Pharmacol. 2019;854:298–306.
  • Gao H, Yu G, Zhang X, et al. BZW2 gene knockdown induces cell growth inhibition, G1 arrest and apoptosis in muscle-invasive bladder cancers: a microarray pathway analysis. J Cell Mol Med. 2019;23(6):3905–3915.
  • Cheng DD, Li SJ, Zhu B, et al. Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway. Oncol Rep. 2017;38(4):2116–2122.
  • Liu J, Yang T, Zhang Y, et al. Promotion of BZW2 by LINC00174 through miR-4500 inhibition enhances proliferation and apoptosis evasion in laryngeal papilloma. Cancer Cell Int. 2020;20:471.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.